Navigation Links
Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
Date:8/7/2008

MEXICO CITY and SAN DIEGO, Aug. 7 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that data was presented from its completed Phase 2a proof-of-concept monotherapy study of RDEA806, the Company's novel investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for patients with human immunodeficiency virus (HIV), demonstrating robust antiviral activity with a well-tolerated profile. An oral presentation of the data was given today by Dr. Graeme Moyle, Director of HIV Research, Chelsea and Westminster Hospital, during a late breaker session at the XVII International AIDS Conference in Mexico City.

"We are extremely pleased that the final results of the Phase 2a study presented today demonstrate that 800 mg once daily produced similar viral load reductions as 400 mg twice daily, providing final confirmation that RDEA806 works equally well given either once or twice daily. Based on the data to date, we continue to believe that RDEA806 has the potential to be a first-line therapy for the treatment of HIV," said Barry D. Quart, PharmD, Ardea's President and CEO. "We look forward to further evaluating RDEA806 and are on track to begin a Phase 2b study comparing once daily doses of RDEA806 to efavirenz (SUSTIVA(R), Stocrin(R)) in first-line patients receiving background treatment with Truvada(R) (emtricitabine and tenofovir disoproxil fumarate), in the third quarter of this year. A recently completed drug interaction study with RDEA806 and Truvada confirmed the lack of drug-drug interactions between these agents, paving the way for initiation of the Phase 2b study."

The Phase 2a randomized, double-blind, placebo-controlled trial evaluated the antiviral activity, pharmacokinetics, safety a
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... IRVINE, Calif. , May 23, 2013 ... breast cancer may not benefit from chemotherapy and still ... announced the launch of one of the largest sources ... The new website and interactive Facebook page provide recently ... if they can safely avoid chemotherapy. "We ...
(Date:5/23/2013)... , May 23, 2013  Every day, their baby ... air to his lungs. April and Bryan Gionfriddo ... predictions weren,t true. "Quite a few doctors said ... alive," says April Gionfriddo , about her ... Anything that would work, we would take it and run ...
(Date:5/23/2013)... May 23, 2013  Spring Bank Pharmaceuticals, Inc., a ... viral infections, today announced that it has initiated dosing ... investigational, once daily, oral therapy for the treatment of ... patients and is designed to assess both the safety ... a first-in-class drug for the treatment of chronic HCV ...
Breaking Medicine Technology:Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 4Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3
... 13, 2011 Reportlinker.com announces that a new market ... UCB S.A.: PharmaVitae Profile ... This analysis examines the historical and forecast performance ... encompasses global company strategy, portfolio and pipeline analysis and ...
... 2011 Zimmer Holdings, Inc. (NYSE: ZMH ; ... the Zimmer NexGen LPS-Flex Mobile Bearing ... the United States.  The LPS-Flex Mobile Bearing knee provides a ... cruciate ligament (ACL), replicating the anatomic center of knee rotation. ...
Cached Medicine Technology:Reportlinker Adds UCB S.A.: PharmaVitae Profile 2Zimmer Introduces a Move Forward in Mobile Bearing Knee Design 2Zimmer Introduces a Move Forward in Mobile Bearing Knee Design 3
(Date:5/24/2013)... This week is National EMS Week, which ... provide the best emergency care and to improve health ... also to educate the public that all can play ... the first link, and a very important one. According ... a cardiac arrest can triple a victim’s chance of ...
(Date:5/24/2013)... hospitalized for heart failure appear to have better odds ... the morning, a new study finds. Death rates ... patients admitted in January, on Fridays and overnight, according ... findings Saturday in Portugal at the annual meeting of ... Cardiology. "The fact that patients admitted right ...
(Date:5/24/2013)... Florida (PRWEB) May 24, 2013 KC and ... the Title Sponsors for FreeRide836. Their oldest sons, Kyle and ... and Tracey Russell family and several professional kiteboarders. , KC ... amazing project. "This has miraculously come together such that virtually ... able to participate." , 20 kite boarders will meet at ...
(Date:5/24/2013)... May 24 (HealthDay News) -- New research suggests ... among people with insomnia. Every additional hour ... 72 percent drop in the likelihood of moderate ... from the University of Pennsylvania. "We ... between sleep duration and suicide risk," study author, ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Gift ... Cards, major competitors in sustainable card material, are ... using forest materials as a sustainable gift card ... to identify industry challenges and increase education and ... programs to support the reduction of carbon footprint ...
Breaking Medicine News(10 mins):Health News:Acadian Medics Reunite with Miracle Baby 2Health News:Monday Best Time for Hospitalization With Heart Failure, Study Says 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3Health News:Sleep Duration Linked to Suicidal Thoughts in People With Insomnia 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 3
... Agitating medicos today sought divine intervention in their anti-quota ... leaders, who were pushing for OBC reservation// in elite ... Post Graduate Institute for Medical Education and Research and ... Gurudwara Nada Sahib to pray to God to give ...
... suffer from rejection of the organ. Hence according ... anti-rejection drug, cyclosporine significantly reduces// rejection and results ... presented at the American Thoracic Society International Conference. ... previously found that inhaled cyclosporine improved survival and ...
... If you thought that, people who actually face tough times ... in life, a startling study has revealed exactly// the contrary. ... such people are the ones who are vulnerable to deception ... ,A six-month study in the University's School of Psychology found ...
... study conducted by researchers at the Washington University and the ... was found// that regular exercise keeps Alzheimer’s at bay. It ... the disease but now it is been disproved by the ... that balance problems and a weak handshake are early signs ...
... has highlighted the beneficial effects of consuming flavanol-rich cocoa ... the Journal of Nutrition//. ,Researchers found that ... appearance of women's skin – increasing hydration, decreasing skin ... defense against UV damage. The German scientists attributed the ...
... same day Prince Charles urges the World Health Assembly ... complementary medicines alongside scientifically// proven treatments, some of UK’s ... into the NHS. ,Thirteen senior doctors who ... medicine have written to every hospital and primary care ...
Cached Medicine News:Health News:Inhaled Cyclosporine Results In Rejection Free Survival among Lung Transplant Patients 2Health News:Take it if you can - Tough Times in Life Churn out Greenhorns 2Health News:Take it if you can - Tough Times in Life Churn out Greenhorns 3Health News:Cocoa good for skin? 2Health News:Eminent Doctors In UK Wants The NHS To Abandon Alternative Medicines: 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: